SCHEMBL6493498

SCHEMBL6493498

CC(=O)N1CCN(C(=O)CCCC(=O)O)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.54
NPC1 O15118 1/20 0.50
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 3/20 0.48
TSHR P16473 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
ITGB3 P05106 4/20 0.47
ITGA2B P08514 4/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
TDP1 Q9NUW8 3/20 0.45
CYP1A2 P05177 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
SLC22A6 Q4U2R8 1/20 0.44
LMNA P02545 2/20 0.43
HSD17B10 Q99714 2/20 0.43
USP2 O75604 1/20 0.43
CYP3A4 P08684 1/20 0.43
HPGD P15428 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6499575 0.88 TDP1 (0.48) ATMKDM4EALDH1A1SMN1; SMN2TDP1
SCHEMBL5605136 0.84 ATM (0.54) ATMNPC1KDM4EALDH1A1TSHR
SCHEMBL10983 0.82 L3MBTL1 (0.62) ATMNPC1KDM4EALDH1A1L3MBTL1
SCHEMBL14500981 0.81 ATM (0.82) ATMNPC1KDM4EALDH1A1TSHR
SCHEMBL5605768 0.81 HSD11B1 (0.53) ATMNPC1KDM4EALDH1A1TSHR
SCHEMBL4497375 0.80 ATM (0.48) ATMNPC1KDM4EALDH1A1SMN1; SMN2
SCHEMBL11928064 0.80 L3MBTL1 (0.71) ATMNPC1ALDH1A1L3MBTL1TDP1
SCHEMBL674349 0.80 ATM (0.79) ATMNPC1KDM4EALDH1A1TSHR
SCHEMBL19754840 0.79 ATM (0.48) ATMNPC1KDM4EALDH1A1TSHR
SCHEMBL16219483 0.79 ATM (0.48) ATMNPC1KDM4EALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1255391-C COLCHINOL derivatives as vascular damaging agents ANGIOGENE PHARM LTD (GB) 2006-05-10 CN disclosed
US-20050277627-A1 Colchinol derivatives as vascular damaging agents ANGIOGENE PHARMACEUTICALS LIMITED (GB) 2005-12-15 US disclosed
CN-1440395-A COLCHINOL derivatives as vascular damaging agents ANGIOGENE PHARM LTD (GB) 2003-09-03 CN disclosed
EP-1301497-A1 COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS Angiogene Pharmaceuticals Limited (GB) 2003-04-16 EP disclosed
WO-2002004434-A1 COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS ANGIOGENE PHARMACEUTICALS LIMITED (GB) 2002-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277627-A1 Colchinol derivatives as vascular damaging agents TOP1, TDP1, TOP2B ATM 1699/4885NPC1 1310/4885KDM4E 3000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.